Inhibition of EGFR signaling delayed but did not block liver regeneration in different experimental models [47, 48] and EGFR inhibitors showed lack of clinical efficacy in human hepatocellular carcinomas [49]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.